Based at the University of Texas Southwestern in Dallas, the registry will be used to collect data, including acute and long-term side effects, to show the impact of the RefleXion X1 system and its onboard fan-beam kilovoltage CT system on patients with solid tumors and lymphoma cancers.

The registry will expand to include biology-guided radiation therapy, which uses PET data to target tumors continuously.

Additionally, the registry will include extensive baseline data and follow-up data collected at the end of treatment, and then again at three, six, nine, 12, 18, and 24 months. A minimum of 750 patients from a minimum of four sites throughout the U.S. will be enrolled in the registry.